AbbVie (NYSE:ABBV) Issues Quarterly Earnings Results

AbbVie (NYSE:ABBV) released its quarterly earnings data on Wednesday. The company reported $2.71 EPS for the quarter, beating the consensus estimate of $2.65 by $0.06, FiscalAI reports. The firm had revenue of $16.62 billion during the quarter, compared to the consensus estimate of $16.39 billion. AbbVie had a negative return on equity of 4,184.47% and a net margin of 6.91%.The company’s quarterly revenue was up 10.0% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.16 earnings per share. AbbVie updated its FY 2026 guidance to 14.370-14.570 EPS and its Q1 2026 guidance to 2.970-3.010 EPS.

Here are the key takeaways from AbbVie’s conference call:

• AbbVie reported a record FY2025 with $61.2B in revenue and adjusted EPS of $10, and guided 2026 revenue to approximately $67B (+9.5%) with adjusted EPS of $14.37–$14.57, above prior expectations.
• Management said Skyrizi and Rinvoq are the primary growth engines — combined sales already eclipsing $25.9B in 2025 and projected to exceed $31B in 2026, driven by strong share capture in psoriasis and IBD.
• AbbVie increased R&D spending and invested heavily in BD (>$5B), adding early‑stage and platform assets — including an in vivo CAR‑T, psychedelic (bretisilocin), trispecific antibodies, a long‑acting amylin analog, and an siRNA platform — to broaden future growth opportunities.
• Persistent headwinds include ongoing Humira erosion (nearly $16B since LOE) and expected Imbruvica IRA pricing pressure, which management says will unfavorably affect oncology growth in 2026.
• AbbVie announced a voluntary U.S. agreement to expand patient access (Medicaid pricing, direct cash‑pay options) while committing $100B in U.S. R&D and capital over the next decade, a move management presents as balancing affordability and protection of innovation.

AbbVie Stock Performance

AbbVie stock opened at $218.44 on Friday. The stock’s 50 day simple moving average is $223.81 and its two-hundred day simple moving average is $219.14. The stock has a market cap of $386.06 billion, a price-to-earnings ratio of 92.56, a PEG ratio of 0.89 and a beta of 0.35. AbbVie has a fifty-two week low of $164.39 and a fifty-two week high of $244.81.

Analyst Ratings Changes

ABBV has been the topic of a number of analyst reports. Hsbc Global Res raised shares of AbbVie from a “hold” rating to a “strong-buy” rating in a report on Wednesday, December 10th. Citigroup dropped their price objective on shares of AbbVie from $235.00 to $230.00 and set a “neutral” rating on the stock in a report on Tuesday, January 27th. BMO Capital Markets reiterated an “outperform” rating and set a $258.00 price objective on shares of AbbVie in a research note on Thursday, January 15th. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $223.00 price target on shares of AbbVie in a report on Wednesday, January 28th. Finally, Morgan Stanley boosted their price target on shares of AbbVie from $269.00 to $270.00 and gave the stock an “overweight” rating in a research note on Thursday. Two analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat, AbbVie currently has a consensus rating of “Moderate Buy” and a consensus price target of $251.00.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Morgan Stanley raised its price target to $270 and kept an overweight rating, signaling analyst confidence that AbbVie’s immunology momentum supports meaningful upside. Read More.
• Positive Sentiment: AbbVie beat Q4 estimates and issued FY‑2026 adjusted EPS guidance above Wall Street consensus, driven by strong Skyrizi and Rinvoq sales — a central bullish thesis for earnings growth and cash generation. Read More. Read More.
• Neutral Sentiment: MarketBeat and some commentators frame the post‑earnings pullback as a buying opportunity, noting heavy institutional ownership and long‑term dividend/cash‑flow support. This view suggests the sell‑off may be technical rather than fundamental. Read More.
• Neutral Sentiment: Some sell‑side and independent analysts (Evercore, others) remain bullish on AbbVie’s immunology momentum and neurology upside, supporting continued accumulation despite near‑term noise. Read More.
• Negative Sentiment: Shares initially gapped down on the earnings reaction — investors focused on weaker Q1/near‑term guidance (Q1 EPS guide below street consensus and lighter revenue outlook), which overshadowed the headline beat. Read More.
• Negative Sentiment: Some analysts and commentaries flagged concentration risk: while Skyrizi and Rinvoq are driving growth, weaknesses in aesthetics and oncology and questions about growth beyond immunology (and reliance on M&A/IPR&D) are prompting investor skepticism. Read More.
• Negative Sentiment: Strategic moves (e.g., Rinvoq’s expanded indications like vitiligo) raise valuation and execution questions for some investors — potential upside if successful, but added near‑term uncertainty. Read More.

Institutional Trading of AbbVie

Institutional investors and hedge funds have recently bought and sold shares of the company. Quarry LP purchased a new position in AbbVie during the third quarter valued at $41,000. Rakuten Securities Inc. lifted its stake in shares of AbbVie by 26.5% during the 2nd quarter. Rakuten Securities Inc. now owns 368 shares of the company’s stock worth $68,000 after acquiring an additional 77 shares during the last quarter. Binnacle Investments Inc increased its holdings in AbbVie by 33.2% during the 2nd quarter. Binnacle Investments Inc now owns 493 shares of the company’s stock worth $92,000 after purchasing an additional 123 shares during the period. Triumph Capital Management bought a new position in shares of AbbVie during the third quarter valued at approximately $193,000. Finally, Turning Point Benefit Group Inc. bought a new position in AbbVie in the third quarter worth about $213,000. 70.23% of the stock is currently owned by institutional investors.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.